Award Synopsis NeoVaxSyn.pdf
PDF 91 KB Posted
- Solicitation number
- 75N93024C00019
About this file
This is an Award Synopsis for contract 75N93024C00019 awarded to NeoVaxSyn, Inc. by the National Institute of Allergy and Infectious Diseases (NIAID) for a nanovaccine research project focused on eliciting broadly neutralizing antibodies against HIV-1.
The contract was awarded on June 25, 2024, with a period of performance from July 1, 2024, through June 30, 2027. The total estimated cost including all options is $2,000,000. The work will be performed at NeoVaxSyn's facility in Ames, Iowa. The contract falls under NAICS code 541715 (Research and Development in the Physical, Engineering, and Life Sciences) and PSC code AN12. The primary point of contact is Christopher Ray (Contract Specialist), with Robert Corno serving as the Contracting Officer.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
AWARD SYNOPSIS
Type: Award
Date of Award: June 25, 2024
Period of Performance (including all options): July 1, 2024 through June 30, 2027
Title: “Nanovaccine for Eliciting Broadly Neutralizing Antibodies against HIV-1”
(RFP) No.: PHS 2020-1
NAICS: 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Contract Number: 75N93024C00019
PSC: AN12
Total Estimated Cost (Including all Options): $2,000,000
Place of Performance/Awardee:
NeoVaxSyn, Inc.
4140 Cochrane Parkway Ames, IA 50014
UEID: EHMTBALCKFE8
Primary Point of Contact at NIAID: Christopher Ray Contract Specialist chris.ray@nih.gov
Secondary Point of Contact at NIAID: Robert Corno Contracting Officer cornorj@niaid.nih.gov mailto:chris.ray@nih.gov mailto:cornorj@niaid.nih.gov
File details come from the government source that posted it. Updated .